-
Impact of intensified prevention measures on rates of hospital-acquired bloodstream infection in medical-surgical intensive care units, Israel, 2011 to 2019
-
View Affiliations Hide AffiliationsDebby Ben-Daviddebbybd tlvmc.gov.il
-
View Collaborators
Members of the National HA-BSI Prevention Working Group: Hiba Zayyad, Kozita Libai, Alona Paz, Mirit Hershman-Sarafov, Bibiana Chazan, Iris Grinberg Avraham, Tal Brosh Nisimov, Nir Maaravi, Maya Kats, Shmuel Benenson, Carmela Schwartz, Ilana Gross, Sarah Israel, Yonatan Oster, Kami Harpaz, Ronza Najjar-Debbiny, Gabriel Weber, Pnina Shitrit, Alia Yassin, Ortal Hilel, Bina Rubinovitch, Pierre Singer, Hefziba Madar, Khetam Hussein, Halima Dabaja-Younis, Tamar Alon, Yonit Wiener-Well, Liora Bier, Lili Goldshtein, Dan Klafter, , Regev Cohen, Danielle Atiya,, Asaf Biber, Elena Machtin, Iris Zohar, Yael CohenView Citation Hide Citation
Citation style for this article: . Impact of intensified prevention measures on rates of hospital-acquired bloodstream infection in medical-surgical intensive care units, Israel, 2011 to 2019. Euro Surveill. 2023;28(25):pii=2200688. https://doi.org/10.2807/1560-7917.ES.2023.28.25.2200688 Received: 25 Aug 2022; Accepted: 05 Mar 2023
Abstract
Central line-associated bloodstream infection (CLABSI) is among the most common preventable infectious complications in patients in intensive care units (ICU). In 2011, the Israel National Center for Infection Control initiated a nationwide CLABSI prevention programme.
To evaluate the impact of different components of the programme on CLABSI and non-CLABSI rates in medical-surgical ICUs.
We included data collected from all 29 medical-surgical ICUs in Israel from November 2011 to December 2019. The study period was divided into three phases: I (baseline, initial CLABSI prevention guidelines introduced, initial feedback on rates provided), II (initial guidelines widely implemented, surveillance undertaken, feedback continued) and III (after implementation of additional prevention measures). Interrupted time series analysis was used to compare CLABSI and non-CLABSI rates during the three phases.
The pooled mean (SD) incidence of CLABSI per 1,000 central line-days dropped from 7.4 (0.38) in phase I to 2.1 (0.13) in phase III (p < 0.001). The incidence rate ratio (IRR) was 0.63 (95% CI: 0.51–0.79) between phases I and II, and 0.78 (95% CI: 0.59–1.02) between phases II and III. The pooled mean (SD) incidence of non-CLABSI per 1,000 patient-days declined from 5.3 (0.24) in phase I to 3.4 (0.13) in phase III (p < 0.001).
National CLABSI prevention guidelines, surveillance and feedback resulted in significant reductions in CLABSI and non-CLABSI rates. In the wake of further interventions, significant reduction was achieved in ICUs reporting improvement in the uptake of additional prevention measures.
Full text loading...